Omeros Long-Term Investments 2010-2024 | OMER
Omeros long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
| Omeros Annual Long-Term Investments (Millions of US $) |
|
|---|---|
| 2023 | $ |
| 2022 | $ |
| 2021 | $ |
| 2020 | $ |
| 2019 | $ |
| 2018 | $ |
| 2017 | $ |
| 2016 | $ |
| 2015 | $ |
| 2014 | $ |
| 2013 | $ |
| 2012 | $ |
| 2011 | $ |
| 2010 | $ |
| 2009 | $ |
| Omeros Quarterly Long-Term Investments (Millions of US $) |
|
|---|---|
| 2024-06-30 | |
| 2024-03-31 | |
| 2023-12-31 | |
| 2023-09-30 | |
| 2023-06-30 | |
| 2023-03-31 | |
| 2022-12-31 | |
| 2022-09-30 | |
| 2022-06-30 | |
| 2022-03-31 | |
| 2021-12-31 | |
| 2021-09-30 | |
| 2021-06-30 | |
| 2021-03-31 | |
| 2020-12-31 | |
| 2020-09-30 | |
| 2020-06-30 | |
| 2020-03-31 | |
| 2019-12-31 | |
| 2019-09-30 | |
| 2019-06-30 | |
| 2019-03-31 | |
| 2018-12-31 | |
| 2018-09-30 | |
| 2018-06-30 | |
| 2018-03-31 | |
| 2017-12-31 | |
| 2017-09-30 | |
| 2017-06-30 | |
| 2017-03-31 | |
| 2016-12-31 | |
| 2016-09-30 | |
| 2016-06-30 | |
| 2016-03-31 | |
| 2015-12-31 | |
| 2015-09-30 | |
| 2015-06-30 | |
| 2015-03-31 | |
| 2014-12-31 | |
| 2014-09-30 | |
| 2014-06-30 | |
| 2014-03-31 | |
| 2013-12-31 | |
| 2013-09-30 | |
| 2013-06-30 | |
| 2013-03-31 | |
| 2012-12-31 | |
| 2012-09-30 | |
| 2012-06-30 | |
| 2012-03-31 | |
| 2011-12-31 | |
| 2011-09-30 | |
| 2011-06-30 | |
| 2011-03-31 | |
| 2010-12-31 | |
| 2010-09-30 | |
| 2010-06-30 | |
| 2010-03-31 | |
| 2009-12-31 | |
| 2009-09-30 | |
| 2009-06-30 | |
| 2009-03-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.246B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $204.059B | 26.03 |
| Stryker (SYK) | United States | $139.868B | 31.52 |
| Boston Scientific (BSX) | United States | $124.863B | 35.90 |
| Medtronic (MDT) | Ireland | $114.537B | 17.04 |
| EssilorLuxottica (ESLOY) | France | $110.799B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.365B | 0.00 |
| Haleon (HLN) | United Kingdom | $44.180B | 28.71 |
| GE HealthCare Technologies (GEHC) | United States | $39.743B | 20.61 |
| ResMed (RMD) | United States | $35.761B | 29.39 |
| Terumo (TRUMY) | Japan | $28.532B | 40.29 |
| Koninklijke Philips (PHG) | Netherlands | $25.454B | 19.48 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.582B | 13.74 |
| Baxter (BAX) | United States | $18.264B | 12.39 |
| Insulet (PODD) | United States | $16.648B | 70.04 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.052B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $10.282B | 35.10 |
| BellRing Brands (BRBR) | United States | $8.726B | 36.90 |
| Demant (WILYY) | Denmark | $8.351B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $8.016B | 19.24 |
| ICU Medical (ICUI) | United States | $4.201B | 40.09 |
| TG Therapeutics (TGTX) | United States | $3.771B | 0.00 |
| Haemonetics (HAE) | United States | $3.763B | 18.61 |
| Envista Holdings (NVST) | United States | $3.662B | 27.28 |
| Prestige Consumer Healthcare (PBH) | United States | $3.657B | 18.22 |
| Perrigo (PRGO) | Ireland | $3.466B | 10.95 |
| Neogen (NEOG) | United States | $3.127B | 36.08 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.988B | 18.00 |
| QuidelOrtho (QDEL) | United States | $2.628B | 16.56 |
| Agios Pharmaceuticals (AGIO) | United States | $2.557B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $2.260B | 38.14 |
| LeMaitre Vascular (LMAT) | United States | $2.165B | 52.65 |
| Curaleaf Holdings (CURLF) | Canada | $2.023B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.960B | 0.00 |
| Warby Parker (WRBY) | United States | $1.769B | 0.00 |
| AtriCure (ATRC) | United States | $1.641B | 0.00 |
| InMode (INMD) | Israel | $1.460B | 8.78 |
| AdaptHealth (AHCO) | United States | $1.365B | 9.85 |
| Verano Holdings (VRNOF) | United States | $1.231B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.179B | 0.00 |
| Evolus (EOLS) | United States | $1.036B | 0.00 |
| Owens & Minor (OMI) | United States | $0.925B | 7.23 |
| National Vision Holdings (EYE) | United States | $0.915B | 29.08 |
| Phibro Animal Health (PAHC) | United States | $0.906B | 18.80 |
| CeriBell (CBLL) | United States | $0.893B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.844B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.747B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.542B | 16.36 |
| Surmodics (SRDX) | United States | $0.536B | 113.85 |
| Quanterix (QTRX) | United States | $0.532B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.515B | 0.00 |
| Valneva SE (VALN) | France | $0.475B | 0.00 |
| ZimVie (ZIMV) | United States | $0.398B | 33.56 |
| Viemed Healthcare (VMD) | United States | $0.331B | 35.54 |
| Aurora Cannabis (ACB) | Canada | $0.328B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.315B | 8.12 |
| TerrAscend (TSNDF) | Canada | $0.309B | 0.00 |
| Jin Medical (ZJYL) | China | $0.308B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.293B | 0.00 |
| Cerus (CERS) | United States | $0.290B | 0.00 |
| Biote (BTMD) | United States | $0.280B | 12.93 |
| Ayr Wellness (AYRWF) | United States | $0.279B | 0.00 |
| Zynex (ZYXI) | United States | $0.255B | 53.33 |
| High Tide (HITI) | Canada | $0.234B | 97.00 |
| MacroGenics (MGNX) | United States | $0.232B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.225B | 15.14 |
| Organigram Holdings (OGI) | Canada | $0.195B | 0.00 |
| Brainsway (BWAY) | Israel | $0.172B | 206.40 |
| FitLife Brands (FTLF) | United States | $0.145B | 19.54 |
| Rockwell Medical (RMTI) | United States | $0.121B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.117B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.113B | 0.00 |
| Veru (VERU) | United States | $0.107B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.097B | 23.90 |
| Fonar (FONR) | United States | $0.092B | 9.51 |
| Jushi Holdings (JUSHF) | United States | $0.092B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.082B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.079B | 0.00 |
| InterCure (INCR) | Israel | $0.079B | 0.00 |
| Modular Medical (MODD) | United States | $0.073B | 0.00 |
| Safety Shot (SHOT) | United States | $0.065B | 0.00 |
| Sanuwave Health (SNWVD) | United States | $0.064B | 1.63 |
| MariMed (MRMD) | United States | $0.062B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.047B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.045B | 0.00 |
| Exagen (XGN) | United States | $0.043B | 0.00 |
| Apyx Medical (APYX) | United States | $0.040B | 0.00 |
| ImmuCell (ICCC) | United States | $0.028B | 0.00 |
| Flora Growth (FLGC) | United States | $0.020B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.015B | 0.00 |
| Nephros (NEPH) | United States | $0.015B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.013B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 17.87 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |